McKesson Corporation (MCK)

In the past six months, McKesson's stock has seen a positive trend, climbing 26.1%. Key events impacting its stock price include strong financial performance with consolidated revenues increasing 19% in the fourth quarter to $90.8 billion and 16% for the full year to $359.1 billion. Growth in key segments such as the U.S. Pharmaceutical segment and the Prescription Technology Solutions segment also contributed. Strategic focus and acquisitions, including the acquisition of PRISM Vision Holdings, LLC in April 2025 and Core Ventures in June 2025, have been key drivers. McKesson announced its intent to separate its Medical-Surgical Solutions business in May 2025. Lower illness season demand impacted foot traffic in primary care settings, leading to headwinds for the Medical-Surgical segment. The company faced challenges in the second quarter of fiscal 2025, including a decline in adjusted operating profit in the Medical-Surgical Solutions segment and rising operational costs in the U.S. Pharmaceutical segment. A significant non-operational drag was a $643 million charge related to the remeasurement of assets under the divestiture of Rexall and Well.ca.

McKesson experiences demand seasonality, particularly in its Prescription Technology Solutions segment and for illness-related products. The fiscal fourth quarter is typically the busiest for Prescription Technology Solutions due to annual insurance verifications. Demand for illness season products can drive variability, while robust demand for specialty pharmaceuticals, including cancer therapies and GLP-1 medications, has been a consistent driver of revenue growth. The U.S. Pharmaceutical segment has shown stable utilization trends and solid volume growth despite seasonal variations in some areas.

McKesson Corporation is a prominent American publicly traded company in the healthcare sector, specifically in medical distribution and healthcare supply chain management. It is the nation's largest healthcare company and the ninth-largest company by revenue in the United States, delivering approximately one-third of all pharmaceutical products consumed in North America. McKesson's core business revolves around healthcare supply chain management, pharmaceutical distribution, and healthcare technology solutions. The company operates through four primary segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. McKesson provides pharmaceutical distribution, medical-surgical supplies, healthcare technology solutions, community oncology services through The US Oncology Network, and biopharma services platforms.

McKesson Corporation has a global presence, with its headquarters in Irving, Texas. The company operates in multiple locations across the globe, emphasizing its international presence and diversified business operations. McKesson delivers a significant portion of pharmaceutical products in North America. Its International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Europe. McKesson Canada is the largest pharmaceutical distributor in Canada. The company also has a 22% equity interest in Nadro, a leading pharmaceutical distributor in Mexico. McKesson has been investing in adding capabilities to its North American distribution footprint.

In the past year, McKesson has been recognized as a "Most Admired Company" by FORTUNE, a "Best Place to Work" by the Human Rights Campaign Foundation, and a top military-friendly company. McKesson's commitment to improving healthcare access and equity, including efforts to diversify clinical trials, contributes to its reputation. The company has also focused on embracing technology and innovation to enhance services and improve patient care. McKesson continues to navigate the financial and reputational impacts of opioid-related claims and has a comprehensive strategy to address these.

McKesson Corporation has a significant institutional ownership base. As of June 23, 2025, there are 2,847 institutional owners and shareholders holding a total of 128,409,972 shares. The largest institutional shareholders include Vanguard Group Inc., BlackRock, Inc., State Street Corp, Massachusetts Financial Services Co /ma/, JPMorgan Chase & Co, Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), Vanguard 500 Index Fund Investor Shares (VFINX), T. Rowe Price Investment Management, Inc., Franklin Resources Inc, and Geode Capital Management, Llc.